3 results
Primary: To evaluate the efficacy and safety of HuMax-CD20 in patients with B-cell Chronic Lymphocytic Leukemia (B-CLL) who have failed fludarabine and alemtuzumabSecondary: To determine the host immune response to HuMax-CD20To determine the…
To assess the effect of two withdrawal strategies over two years in patients with stable remission for more than 8 months on combination therapy with infliximab and antimetabolites, and demonstrate that continued combination of infliximab and…
Primary:• To evaluate the effect of efgartigimod IV compared to placebo on CRESSSecondary:• To evaluate the effect of efgartigimod IV compared to placebo on the histology of the parotid gland (selected sites only)• To evaluate the safety of…